- Trials with a EudraCT protocol (169)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
169 result(s) found for: Three Rs.
Displaying page 1 of 9.
EudraCT Number: 2018-001702-28 | Sponsor Protocol Number: MedOPP199 | Start Date*: 2018-11-27 | |||||||||||
Sponsor Name:Medica Scientia Innovation Research (MEDSIR) | |||||||||||||
Full Title: Neoadjuvant Letrozole and Palbociclib in patients with Stage II-IIIb breast cancer, HR (+) / HER2 (-) phenotype and Intermediate (18-25) or High (>25) Recurrence-Score by Oncotype-DX; analysis of R... | |||||||||||||
Medical condition: Early HR(+)/HER2(-) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005036-28 | Sponsor Protocol Number: 2012/41 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:CENTRE ANTOINE LACASSAGNE | |||||||||||||
Full Title: Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate | |||||||||||||
Medical condition: Prostate cancer metastatic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001340-62 | Sponsor Protocol Number: 208068 | Start Date*: 2019-01-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||
Full Title: A study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational unadjuvanted RSV maternal vaccine compared to placebo when administered to healthy non-pregnant... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Prevention of RSV LRTI in infants) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) DE (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000117-76 | Sponsor Protocol Number: 204838 | Start Date*: 2016-09-27 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline S.A. | |||||||||||||||||||||||
Full Title: A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ respiratory syncytial virus (RSV) ... | |||||||||||||||||||||||
Medical condition: Active immunization of infants for the prevention of any lower respiratory tract infections (LRTI; bronchiolitis and [broncho]pneumonia) associated with respiratory syncytial virus (RSV [subtypes A... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) PL (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001462-17 | Sponsor Protocol Number: WSG-AM06 | Start Date*: 2012-03-29 | |||||||||||
Sponsor Name:Westdeutsche Studiengruppe GmbH | |||||||||||||
Full Title: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer | |||||||||||||
Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000576-42 | Sponsor Protocol Number: ICORG12-01 | Start Date*: 2012-04-05 | |||||||||||
Sponsor Name:Cancer Trials Ireland | |||||||||||||
Full Title: S1007, A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer ... | |||||||||||||
Medical condition: Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002590-22 | Sponsor Protocol Number: NN9924-4338 | Start Date*: 2019-07-25 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004175-73 | Sponsor Protocol Number: HP-CD-CL-2002 | Start Date*: 2017-09-27 | |||||||||||
Sponsor Name:Herantis Pharma Plc | |||||||||||||
Full Title: A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administere... | |||||||||||||
Medical condition: Idiopathic Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000992-18 | Sponsor Protocol Number: 12-016 | Start Date*: 2014-09-26 |
Sponsor Name:UMC Utrecht | ||
Full Title: Proactive versus reactive inhibition in ADHD: Genetics, neurobiology and pharmacology | ||
Medical condition: Attention-Deficit Hyperactivity Disorder (ADHD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000453-44 | Sponsor Protocol Number: NL42746.058.12 | Start Date*: 2013-06-19 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: The full scope of oxytocinergic influences on the parental brain: Maternal defensiveness and grandparent-child interactions | |||||||||||||
Medical condition: There are no medical conditions or diseases under investigation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002232-82 | Sponsor Protocol Number: KIH18001 | Start Date*: 2019-07-25 |
Sponsor Name:Karolinska Institutet | ||
Full Title: Downstream targets of SSRI effect in treatment of Major Depressive Disorder | ||
Medical condition: Major depressive disorder (MDD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004323-33 | Sponsor Protocol Number: AC102-201 | Start Date*: 2022-05-06 |
Sponsor Name:AudioCure Pharma GmbH | ||
Full Title: Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic ... | ||
Medical condition: Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) ISSNHL is most commonly defined as sensorineural hearing loss of 30dB or greater over at least three contiguous audiometric frequencies occurri... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) BG (Prematurely Ended) AT (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000346-19 | Sponsor Protocol Number: HP-CD-CL-2003 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:Herantis Pharma Plc | |||||||||||||
Full Title: A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-C... | |||||||||||||
Medical condition: Idiopathic Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001026-89 | Sponsor Protocol Number: 25874 | Start Date*: 2005-07-14 | |||||||||||
Sponsor Name:Serono GmbH | |||||||||||||
Full Title: Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple scle... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with relapses | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001801-29 | Sponsor Protocol Number: 1298.3 | Start Date*: 2011-10-26 |
Sponsor Name:Boehringer Ingelheim | ||
Full Title: A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Ti... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-002378-26 | Sponsor Protocol Number: STRIX-MSext001 | Start Date*: 2014-11-13 | |||||||||||
Sponsor Name:Västerbottens Läns Landsting | |||||||||||||
Full Title: Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy app... | |||||||||||||
Medical condition: The original trial (EudraCT 2010-023021-38) recruited 74 patients with relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (D... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002589-38 | Sponsor Protocol Number: NN9924-4309 | Start Date*: 2019-08-26 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: PIONEER 12 China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes mellitus treated with metformin | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000174-37 | Sponsor Protocol Number: GEICAM/2011-03_S1007 | Start Date*: 2012-04-26 | |||||||||||
Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | |||||||||||||
Full Title: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Re... | |||||||||||||
Medical condition: Patients with confirmed diagnosis of node positive (1-3 nodes) invasive breast carcinoma with positive hormone receptor status, and negative HER-2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003219-20 | Sponsor Protocol Number: NN9535-4386 | Start Date*: 2018-09-13 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-ce... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) SI (Completed) EE (Completed) BG (Completed) LV (Completed) PL (Completed) GR (Completed) DE (Completed) CZ (Completed) LT (Completed) PT (Completed) ES (Completed) HR (Completed) HU (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004019-29 | Sponsor Protocol Number: CAIN457B2203 | Start Date*: 2013-04-29 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple ... | |||||||||||||
Medical condition: Relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) IT (Temporarily Halted) SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) ES (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
